Triglav Skladi D.O.O. Makes New Investment in Illumina, Inc. (NASDAQ:ILMN)

Triglav Skladi D.O.O. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,500 shares of the life sciences company's stock, valued at approximately $1,403,000.

Several other large investors also recently modified their holdings of the company. Capital World Investors increased its position in shares of Illumina by 408.6% during the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after buying an additional 14,481,232 shares during the period. WCM Investment Management LLC grew its holdings in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after purchasing an additional 867,673 shares during the period. Bank of New York Mellon Corp grew its holdings in Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after purchasing an additional 27,618 shares during the period. Brown Advisory Inc. grew its holdings in Illumina by 54,220.9% in the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock worth $255,586,000 after purchasing an additional 1,909,118 shares during the period. Finally, Norges Bank acquired a new stake in Illumina in the fourth quarter worth $228,714,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Illumina

In related news, CFO Ankur Dhingra purchased 6,100 shares of the business's stock in a transaction dated Monday, May 12th. The stock was acquired at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the purchase, the chief financial officer now directly owns 24,906 shares of the company's stock, valued at $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.60% of the company's stock.

Illumina Stock Up 1.5%

ILMN traded up $1.17 on Thursday, reaching $80.54. The company's stock had a trading volume of 1,983,225 shares, compared to its average volume of 2,322,136. The stock has a 50 day moving average of $78.33 and a two-hundred day moving average of $110.03. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $12.75 billion, a price-to-earnings ratio of -10.49, a P/E/G ratio of 1.60 and a beta of 1.35. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.03 billion. During the same quarter in the previous year, the business earned $0.98 earnings per share. The firm's revenue for the quarter was down 1.4% on a year-over-year basis. As a group, analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of research reports. Canaccord Genuity Group reduced their price target on shares of Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a report on Monday, May 12th. Citigroup reduced their price target on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a report on Monday, April 7th. Robert W. Baird reduced their price objective on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $128.15.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.